Eli Lilly and Co
SWB:LLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Eli Lilly and Co
SWB:LLY
|
US |
|
M
|
Megachem Thailand PCL
SET:MGT
|
TH |
|
Strike Resources Ltd
ASX:SRK
|
AU |
|
D
|
DDC Enterprise Ltd
AMEX:DDC
|
CN |
|
Cogent Communications Holdings Inc
NASDAQ:CCOI
|
US |
|
Manugraph India Ltd
NSE:MANUGRAPH
|
IN |
|
Melia Hotels International SA
F:MEL
|
ES |
|
XMReality AB (publ)
OTC:XMMRF
|
SE |
|
Perenti Global Ltd
ASX:PRN
|
AU |
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
UK |
|
Fsn E-Commerce Ventures Ltd
NSE:NYKAA
|
IN |
Wall Street
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for
LLY
is 1 033.1 EUR
with a low forecast of 705.84 EUR and a high forecast of 1 326.14 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LLY's stock price target?
Price Target
1 033.1
EUR
According to Wall Street analysts, the average 1-year price target for
LLY
is 1 033.1 EUR
with a low forecast of 705.84 EUR and a high forecast of 1 326.14 EUR.
What is Eli Lilly and Co's Revenue forecast?
Projected CAGR
19%
For the last 14 years the
compound annual growth rate for
Eli Lilly and Co's revenue is
7%.
The projected
CAGR
for the next 3 years is
19%.
What is Eli Lilly and Co's Operating Income forecast?
Projected CAGR
22%
For the last 14 years the
compound annual growth rate for
Eli Lilly and Co's operating income is
12%.
The projected
CAGR
for the next 3 years is
22%.
What is Eli Lilly and Co's Net Income forecast?
Projected CAGR
32%
For the last 14 years the
compound annual growth rate for
Eli Lilly and Co's net income is
12%.
The projected
CAGR
for the next 3 years is
32%.
